Takeda Pharmaceutical said on January 30 that it has filed a new Japanese drug application for the antibody drug conjugate (ADC) mirvetuximab soravtansine, targeting folate receptor alpha (FRα)-positive, platinum-resistant recurrent ovarian cancer (PROC). The drug has been designated as an…
To read the full story
Related Article
- Takeda Snags Japan Rights to ImmunoGen’s ADC
August 30, 2023
BUSINESS
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
- Sawai to End Teribone Generic Sales following Patent Settlement
February 26, 2026
- Darzquro Seen as Emerging Standard in High-Risk SMM: Specialist
February 26, 2026
- Towa Wins Pediatric Autism Use for Abilify Generic
February 26, 2026
- Jardiance Tops Five Promotion Channels in January: Intage
February 26, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





